Cargando…

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD

Many patients with chronic obstructive pulmonary disease (COPD) receive inhaled corticosteroids (ICSs) without a clear indication, and thus, the impact of ICS withdrawal on disease control is of great interest. DACCORD is a prospective, noninterventional 2-year study in the primary and secondary car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vogelmeier, Claus, Worth, Heinrich, Buhl, Roland, Criée, Carl-Peter, Lossi, Nadine S, Mailänder, Claudia, Kardos, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295250/ https://www.ncbi.nlm.nih.gov/pubmed/28203072 http://dx.doi.org/10.2147/COPD.S125616

Ejemplares similares

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

A year in the life of German patients with COPD: the DACCORD observational study
por: Buhl, Roland, et al.
Publicado: (2016)

The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methods
por: Kardos, Peter, et al.
Publicado: (2015)

Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study
por: Vogelmeier, Claus F., et al.
Publicado: (2022)

COPD Assessment Test Changes from Baseline Correlate with COPD Exacerbations: A Longitudinal Analysis of the DACCORD Observational Study
por: Kardos, Peter, et al.
Publicado: (2020)

In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations
por: Worth, Heinrich, et al.
Publicado: (2023)

Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany
por: Worth, Heinrich, et al.
Publicado: (2021)

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
por: Avdeev, Sergey, et al.
Publicado: (2019)

Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal
por: Yawn, Barbara P, et al.
Publicado: (2016)

Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice
por: Cataldo, Didier, et al.
Publicado: (2018)

Pragmatic trial on inhaled corticosteroid withdrawal in patients with COPD in general practice
por: van den Bemt, Lisette, et al.
Publicado: (2020)

Withdrawal of Inhaled Corticosteroids in Patients with COPD – A Prospective Observational Study
por: Nielsen, Anne Orholm, et al.
Publicado: (2021)

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
por: Vestbo, Jørgen, et al.
Publicado: (2019)

A descriptive cohort study of withdrawal from inhaled corticosteroids in COPD patients
por: Patel, Smit, et al.
Publicado: (2022)

Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial
por: Choudhury, Aklak B, et al.
Publicado: (2007)

Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology
por: Nadeem, Nighat J, et al.
Publicado: (2011)

The sputum transcriptome better predicts COPD exacerbations after the withdrawal of inhaled corticosteroids than sputum eosinophils
por: Ditz, Benedikt, et al.
Publicado: (2021)

Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences
por: Lutter, Johanna I, et al.
Publicado: (2021)

Rational use of inhaled corticosteroids for the treatment of COPD
por: Quint, Jennifer K., et al.
Publicado: (2023)

Perceptions of COPD patients of the proposed withdrawal of inhaled corticosteroids prescribed outside guidelines: A qualitative study
por: Gilworth, Gill, et al.
Publicado: (2019)

Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)

Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study
por: Jo, Taisuke, et al.
Publicado: (2020)

Inhaled Corticosteroids Prescribed for COPD Patients with Mild or Moderate Airflow Limitation: Who Warrants a Trial of Withdrawal?
por: Harries, Timothy H, et al.
Publicado: (2019)

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
por: Micheletto, Claudio, et al.
Publicado: (2019)

One More Time: The Impact of Inhaled Corticosteroid Withdrawal on IMPACT
por: Han, MeiLan K., et al.
Publicado: (2020)

Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA
por: Kardos, Peter, et al.
Publicado: (2018)

Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study
por: Magnussen, Helgo, et al.
Publicado: (2021)

Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013)

Inhaled corticosteroids in COPD: Personalising the therapeutic choice
por: Shaw, J A, et al.
Publicado: (2018)

How inhaled corticosteroids target inflammation in COPD
por: Lea, Simon, et al.
Publicado: (2023)

Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations
por: Glaab, Thomas, et al.
Publicado: (2010)

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial
por: Tashkin, Donald P., et al.
Publicado: (2018)

Withdrawal of inhaled corticosteroids from patients with COPD with mild or moderate airflow limitation in primary care: a feasibility randomised trial
por: Harries, Timothy H, et al.
Publicado: (2022)

Inhaled Corticosteroids
por: Barnes, Peter J.
Publicado: (2010)

Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD
por: Kim, Sae Ahm, et al.
Publicado: (2016)

Inhaled corticosteroids and angiotensin-converting enzyme-2 in COPD
por: Lipworth, Brian, et al.
Publicado: (2021)

Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)
por: Rossi, Andrea, et al.
Publicado: (2014)

Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany
por: Glaab, Thomas, et al.
Publicado: (2012)

Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany – The TriOptimize Study
por: Gessner, Christian, et al.
Publicado: (2022)

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
por: Maltais, François, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r6qb6lt8fpnf9e36dj3bg4dsba